- Home
- RLAY vs RCUS Comparison
RLAY vs RCUS Comparison
Compare RLAY & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | RCUS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.8B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RLAY | RCUS |
|---|---|---|
| Price | $18.37 | $30.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 10 |
| Target Price | $19.50 | ★ $31.90 |
| AVG Volume (30 Days) | ★ 4.1M | 1.6M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,355,000.00 | ★ $247,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $324.03 | $45.62 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.44 | N/A |
| 52 Week Low | $3.03 | $8.03 |
| 52 Week High | $19.93 | $31.74 |
Technical Indicators
Market Signals| Indicator | RLAY | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 64.92 | 65.68 |
| Support Level | $6.67 | $19.78 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.03 | 1.61 |
| MACD | 0.21 | 0.48 |
| Stochastic Oscillator | 77.66 | 83.40 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.